James E. Tcheng, MD
- Medicine / Medicine - Cardiology
- Community and Family Medicine / CFM - Medical Informatics
Address
DUMC 2708
Durham, NC 27710
2424 Erwin Road, Suite 403
Durham, NC 27705
Durham, NC 27710
Appointment Telephone
919-681-5816
Office Telephone
919-668-8796
Fax Telephone
919-668-7097
- MD, Johns Hopkins University School of Medicine (Maryland), 1978-1982
- Medicine, Barnes Hospital (Washington), 1982-1985
- Cardiology, Duke University Medical Center, 1986-1988
Clinical Interests
Coronary artery disease, coronary angioplasty, stent implantation, atherectomy,
laser angioplasty, chronic total coronary occlusions, antiplatelet therapy,
antithrombin therapy, clinical trials, information technology, medical
informatics
Research Interests
In addition to my clinical responsibilities as an interventional cardiologist, my research interests include the study of antithrombotic therapies in cardiovascular disease and biomedical informatics and information technologies.
My research is applied (clinical research), primarily focusing on the evaluation of technologies in the clinical arena.
I have participated in numerous clinical trials and have also conducted several multicenter studies, including the EPIC, PROLOG, EPILOG, EPISTENT, IMPACT, IMPACT II, TOTAL, PRIDE, ESPRIT, MEND-1, and ELECT Trials.
My areas of expertise are an outgrowth of my clinical research, and includes use of the new antiplatelet therapeutics in the treatment of coronary artery disease; treatment of unstable angina and acute myocardial infarction; quality assurance and quality improvement; application of informatics and information technology to the delivery of care; and the application of excimer laser coronary angioplasty in the treatment of coronary artery disease.
Key words: angioplasty, excimer laser, platelet glycoproteins, computers, clinical trials.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- American College of Cardiology Foundation
- American Medicolegal Foundation
- AstraZeneca
- Eli Lilly & Co.
- Ischemix, Inc.
- Merck Sharpe & Dohme (Merck & Co, USA)
- Philips Medical Systems
- Sanofi-Aventis
Representative Publications
Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation. 2010 Feb 16;121(6):784-91.
(2010)
Abstract
Guerra DR, Tcheng JE. Prasugrel: Clinical development and therapeutic application. Adv Ther. 2009 Nov;26(11):999-1011.
(2009)
Abstract
Tcheng JE, Lim IH, Srinivasan S, Jozic J, Gibson CM, O'Shea JC, Puma JA, Simon DI. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circ Cardiovasc Interv. 2009 Feb;2(1):43-51.
(2009)
Abstract
Tcheng JE, Zidar DA. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. JACC Cardiovasc Interv. 2009 Dec;2(12):1266-8.
(2009)
Abstract
Casterella PJ, Tcheng JE. Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. Am Heart J. 2008 May;155(5):781-90.
(2008)
Abstract
Denardo SJ, Davis KE, Tcheng JE. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. Am J Cardiol. 2007 Nov 1;100(9):1376-82.
(2007)
Abstract
Dery JP, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O'Shea JC, Tcheng JE, . Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43-50.
(2007)
Abstract
Musser RC, Tcheng JE. Quantitative and qualitative comparison of text-based and graphical user interfaces for Computerized Provider Order Entry. AMIA Annu Symp Proc. 2006:1041.
(2006)
Abstract
Puma JA, Banko LT, Pieper KS, Sacchi TJ, O'Shea JC, Dery JP, Tcheng JE. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J Am Coll Cardiol. 2006 Feb 21;47(4):715-8.
(2006)
Abstract
Tcheng JE, Kinney KG. After fibrinolysis: is cardiac catheterization the answer? J Am Coll Cardiol. 2006 Oct 3;48(7):1336-8.
(2006)
Abstract
Tcheng JE. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. J Interv Cardiol. 2006 Oct;19(5):456-63.
(2006)
Abstract
